Abstract Details

Title Impact of Duration and Size of Enhancement in the Formation and Outcome of MS Black Holes: Analysis of the BECOME Study

Topic MS and Related Diseases

Presentation(s) P07 - (-)

Poster/Presentation
Number 122

Objective

Background BACKGROUND: Duration and size of gadolinium enhancement in new brain MS lesions may predispose to conversion to CBH.

Design/Methods DESIGN/METHODS: The BECOME study was optimized to detect GAD (+) lesions in MS patients undergoing monthly 3T MRI with triple dose gadolinium scans for up to 24 consecutive months following randomization to interferon beta-1b or glatiramer acetate. Twenty three patients with 116 new GAD (+) lesions that resulted in CBH were included in this study. CBH were defined as T1 hypointensities that last >12 months. From their MRI scans with new lesions that formed CBH we also selected one new GAD (+) lesion that resulted in a transient black hole (TBH) and one that did not (NBH), for comparison. The size of the GAD (+) lesions was measured in square millimeters using the best-fit polygonal tool of the PACS image analysis software (GE health care). Duration of enhancement was defined as first detection to first disappearance using the monthly scans.

Results RESULTS: The mean duration of gadolinium enhancement in new brain lesions that formed CBH was 2.3 months compared to 2 months for TBH and 1.2 months for NBH (p<0.001 for new GAD (+) lesions resulting in CBH versus NBH and p=0.53 for the comparison with TBH). New GAD (+) lesions that evolved into CBH had a mean largest size of 51.3mm[sup2] compared to 11.9 mm[sup2] for TBH and 8.6 mm[sup2]for NBH (p<0.001 for both the comparison of new GAD (+) lesions that resulted in CBH versus TBH and versus NBH).

Conclusions CONCLUSIONS: Formation of black holes from new brain lesions appears related to the duration of gadolinium enhancement while their persistence (CBH) appears to be related to the lesion enhancement size.

Authors/Disclosures
Stuart D. Cook, MD, FAAN (Rutgers) PRESENTER	No disclosure on file
Jojy V. Cheriyan, MD	No disclosure on file
	No disclosure on file
Diego Cadavid, MD, FAAN (Verge Genomics)	Dr. Cadavid has received personal compensation for serving as an employee of Verge Genomics. Dr. Cadavid has received personal compensation for serving as an employee of Vertex Pharmaceuticals. Dr. Cadavid has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Cadavid has or had stock in Verge Genomics.Dr. Cadavid has or had stock in Vertex Pharmaceuticals.
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.

��ɫ��

��ɫ��